Replies to post #7072 on Revance Therapeutics Inc (RVNC)

[go seek]

Of course Revance Therapeutics will survive. Highly respected dermatologists tout DAXXIFY as A Best in Class Product and the first true innovation in the space in 30 years. Management has adjusted its marketing strategy. Engage with customers through competitive pricing and enhanced messaging that highlights DAXXIFY’s unique peptide formulation, long duration, fast onset and improved skin quality appearance. New patients love the product. Daxi sales should exceed expectations going forward. RHA Collections sales are solid, more excellent products with high growth potential. ADD in potential partnerships and marketing opportunities outside the US.

[vinmantoo]

Interesting post but it contains key factual errors. The first is that the Fed isn’t continuing to tighten. It stopped some time ago and is waiting for the right time to cut rates. Second, inflation is under control as it was reading just above the Fed’s 2% target. As far as inflation, it was supply chain bottlenecks as we came out of the pandemic combined with disruptions in the energy markets and in geopolitical stability due to Russia’s war on Ukraine that drove the inflation spikes. Corporate greed now is driving a portion of inflation now.


As far as ENTA, you didn’t follow it but feel you need to comment on its current low state. Many people including myself profited from it’s HepC drugs and some of us invested some of that money back as ENTA price dropped, one of them is myself.